| Paul Hudson |
Paul Hudson currently works at Sanofi, as Chief Executive Officer & Executive Director from 2019 and Novartis Pharma KK, as Chairman. Mr. Hudson also formerly worked at Novartis Pharmaceuticals Corp., as Chief Executive Officer from 2016 to 2019, Sanofi Clir SNC, as Chief Executive Officer & Director, AstraZeneca KK, as President & Director, AstraZeneca PLC, as President-AstraZeneca US & EVP-North America from 2006 to 2016, Novartis AG, as Member-Executive Committee, AstraZéneca Farmacéutica Spain SA, as President, and Schering Plough Holdings France SAS, as Head-Global Marketing. Mr. Hudson received his undergraduate degree from Manchester Metropolitan University. |
| Madeleine Roach |
Madeleine Roach currently works at Sanofi, as Executive Vice President-Business Operations from 2023. Ms. Roach also formerly worked at AstraZeneca GmbH, as Head-Global Finance Services Asia Pacific. Ms. Roach received her undergraduate degree from the University of London. |
| Houman Ashrafian |
Houman Ashrafian was the founder of Heart Metabolics Ltd. (2014), HMBL Ltd. (2004), and TRex Bio Ltd. (2018) as Director. Dr. Ashrafian is also the founder of Dualitas Ltd., Catamaran Bio, Inc., Weatherden Ltd., Sitryx Therapeutics Ltd., Alchemab Therapeutics Ltd., Mestag Therapeutics Ltd., Enara Bio Ltd. Dr. Ashrafian is currently a Director at Ervaxx Ltd. since 2016, Zarodex Therapeutics Ltd. since 2017, Cellinta Ltd. since 2020, Cybele Therapeutics Ltd. since 2019, a Scientific Advisor at SV Health Investors LLP since 2016, a Managing Partner at SV Health Managers LLP since 2016, and Executive VP, Head-Research & Development at Sanofi since 2023. Former positions include Chairman at Therini Bio, Inc., Director at Imbria Pharmaceuticals, Inc., and Director at Prilenia Therapeutics BV. Education includes an undergraduate degree from the University of Oxford (1999), a doctorate from the University of Oxford (2009), and undergraduate and graduate degrees from the University of Cambridge. |
| Preethi Sundaram |
Preethi Sundaram currently works at Sanofi, as Director-Global Clinical Research and Catalyst Pharmaceuticals, Inc., as Chief Strategy Officer from 2022. Dr. Sundaram received her undergraduate degree from the University of Madras, Masters Business Admin degree from London Business School, doctorate degree from the University of Anglia Ruskin, and undergraduate degree from Birla Institute of Technology & Science. |
| Raj Verma |
Raj Verma has a current job as the Chief Diversity, Culture & Experience Officer at Sanofi. |
| Emmanuel Frenehard |
Emmanuel Frenehard currently works at Sanofi, as Chief Digital Officer & Executive Vice President from 2023. Mr. Frenehard received his graduate degree from Institut Supérieur de Gestion and undergraduate degree from EBS Universität für Wirtschaft und Recht gGmbH. |
| François-Xavier Michel Marie Roger |
François-Xavier Michel Marie Roger currently works at Les Prés Fleuris-Stiftung, as Member and Sanofi, as Chief Financial Officer from 2024. Mr. Roger also formerly worked at Britannia Industries Ltd., as Director, Comvik International (Vietnam) AB, as Director, Nestle Health Science SA, as Director, Hoechst Marion Roussel SA de CV, as Finance Director, Sandoz AG, as Director, Takeda Pharmaceutical Co., Ltd., as Chief Financial Officer & Director from 2014 to 2015, Sandoz Group AG, as Non-Executive Director from 2023 to 2024, Millicom International Cellular SA, as Chief Financial Officer & Senior Executive VP in 2013, Danone SA, as Vice President-Corporate Finance, Roussel Uclaf SA, as Senior Controller, Aventis Pharma Japan, as Vice President-Finance, Nestlé SA, as Chief Financial Officer & Executive Vice President from 2015 to 2024, and Danone Asia Pte Ltd., as Chief Financial Officer from 2000 to 2008. Mr. Roger received his Masters Business Admin degree from The Ohio State University and graduate degree from Audencia. |
| Natalie Bickford |
Natalie Bickford currently works at Women 1st Ltd., as Chairman, Kronos, Inc., as Director-Kronos Workforce Institute, Sanofi, as Chief People Officer & Executive Vice President from 2020, and Bryanston School, Inc., as Member-Governors Board from 2017. Ms. Bickford also formerly worked at People 1st, as Deputy Chairman, Merlin Entertainments Ltd., as Director-Group Human Resources, Sodexho Ltd., as Director-Human Resources, AstraZeneca SAS, as Director-Human Resources from 2006 to 2008, Barclays PLC, as Manager, The Prince's Trust, as Member-Women's Leadership Group, and Kingfisher plc, as Principal from 1999 to 2006. Ms. Bickford received her undergraduate degree from the University of Warwick. |
| Frédéric Oudéa |
Mr. Frédéric Oudéa is an Independent Chairman at Sanofi, a Chairman at Fondation Ecole Polytechnique, a President at Fédération Bancaire Française, a Lead Independent Director at Capgemini SE, an Independent Director at Capgemini Italia SpA and an Independent Director at Capgemini Service SAS. He is on the Board of Directors at Ecole Polytechnique, Capgemini SE, Institut Europlace de Finance, Capgemini Italia SpA and Capgemini Service SAS. Mr. Oudéa was previously employed as a Vice Chairman by Capgemini Technology Services India Ltd., a President by European Banking Federation aisbl, a Chief Executive Officer by Société Générale SA (Broker), and a Chief Executive Officer & Director by Société Générale SA. He also served on the board at ALD SA and Societe Generale SA (London Branch). He received his undergraduate degree from Ecole Polytechnique and an undergraduate degree from Ecole Nationale d'Administration. |
| Emmanuel Andre Marie Babeau |
Emmanuel Andre Marie Babeau currently works at Davide Campari-Milano NV, as Independent Non-Executive Director, Schneider Electric (China) Co. Ltd., as Director, Schneider Electric Holdings, Inc., as Director, Schneider Electric Usa, Inc., as Director, Samos Acquisition Co. Ltd., as Director, Carros Sensors Topco Ltd., as Director from 2014, Vectura Group Ltd., as Director from 2021, Aster Capital Partners SAS, as Member-Supervisory Board, Philip Morris International, Inc., as Chief Financial Officer from 2020, Custom Sensors & Technology SAS, as Member-Supervisory Board, and Sci Getij, as Managing Partner. Mr. Babeau also formerly worked at Schneider Electric SE, as Deputy Chief Executive Officer-Finance & Legal from 2013 to 2020, Aveva Group Ltd. (United Kingdom), as Vice Chairman from 2018 to 2020, Schneider Electric Services International SRL, as Chairman & Member-Management Board, Sodexo SA, as Independent Director from 2016 to 2021, Invensys Ltd., as Director from 2014 to 2018, Pernod Ricard SA, as CFO & Group Deputy Managing Director from 2003 to 2009, Telvent GIT SA, as Director, Sanofi, as Independent Director from 2018 to 2020, Sanofi SA, as Director from 2018 to 2020, AVEVA Solutions Ltd., as Director from 2018 to 2019, Schneider Electric France SAS, as Director, Schneider Electric Industries SASU, as Director, Schneider Electric Taiwan Co. Ltd., as Director, Carros Sensors Holdco Ltd., as Director, Transformateurs SAS, as Director, Schneider Electric Energy Access SAS, as Director, Schneider SA, as Member-Management Board, Schneider Electric Ltd., as Chief Financial Officer, and Innovista Sensors SAS, as Member-Supervisory Board. Mr. Babeau received his undergraduate degree in 1989 from ESCP Europe Campus Paris. |
| Lise Kingo |
Lise Kingo currently works at Imperial College London, as Chairman-Leonardo Centre, Danone SA, as Director from 2022, Sanofi, as Independent Director from 2020, Learning Disabilities Association, Inc. (Minnesota), as Ex-Officio Director, Covestro AG, as Member-Supervisory Board from 2021, Prince of Wales, as Member, and Covestro Deutschland AG, as Member-Supervisory Board. Ms. Kingo also formerly worked at United Nations Global Compact, as Chief Executive Officer & Executive Director from 2015 to 2020, GN Store Nord A, as Deputy Chairman from 2005 to 2009, Steno Diabetes Center A, as Chairman from 2010 to 2014, Danish Council On Corporate Social Responsibility, as Chairman from 2012 to 2015, Danmarks Naturfredningsforening, as Deputy Chairman from 2015 to 2020, Novozymes A, as Director-Corporate Environmental Affairs from 1988 to 1999, Sanofi SA, as Independent Director, Grieg Star Shipping AS, as Independent Director from 2012 to 2015, PRI Association, as Director from 2015 to 2020, Aker Horizons ASA, as Independent Director from 2021 to 2023, Novo Nordisk A, as Chief of Staff & Executive Vice President from 2013 to 2014, Novo Holdings A, as Senior Vice President-Stakeholder Relations from 1999 to 2002, and Vrije Universiteit Amsterdam, as Professor from 2012 to 2015. Ms. Kingo received her graduate degree in 2000 from the University of Bath, undergraduate degree in 1991 from Copenhagen Business School, and undergraduate degree in 1986 from the University of Aarhus. |
| Emile Voest |
Emile Voest is the founder. Dr. Voest is the founder of Hartwig Medical Foundation, serving as Non-Executive Director since 2015. Dr. Voest was the founder of Hubrecht Organoid Technology Foundation, serving as Medical Director from 2013 to 2016. Dr. Voest is the founder of Center For Personalized Cancer Therapy, serving as Director since 2010. Dr. Voest is also the founder of Mosaic Therapeutics Ltd. Dr. Voest is currently an Independent Director at Sanofi since 2022. Dr. Voest is currently a Professor at the University of Utrecht since 1999. Former positions include Director at the European Society for Medical Oncology from 2015 to 2020 and Executive Medical Director at Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenh from 2014 to 2020. Education includes a doctorate from the University of Utrecht. |
| Thomas C. Südhof |
Thomas C. Südhof is the founder of Reata Pharmaceuticals, Inc. (2002), Circuit Therapeutics, Inc. (2011), and Neucyte, Inc. (2017). He is also the founder of Recognify Life Sciences, Inc. Dr. Südhof's current jobs include Independent Director at Sanofi (since 2016), Independent Director at CytoDel LLC (since 2021), Member of the Scientific Advisory Board at Simcere Pharmaceutical Group Ltd., Member of The Royal Society (since 2017), Member of the National Academy of Sciences (since 2002), Member of the American Academy of Arts & Sciences (since 2010), Member of the National Academy of Medicine (United States) (since 2007), Member of Deutsche Akademie der Naturforscher Leopoldina eV (since 2015), Professor at Stanford University School of Medicine, Venture Partner at Catalio Capital Management LP, and Member of the Scientific Advisory Board at Jupiter Therapeutics, Inc. He is also a former Independent Director at Abide Therapeutics, Inc. (2019-2020), Member-Neuroscience Review Board at Genentech, Inc. (2013-2016), Assistant Professor at The University of Texas Southwestern Medical Center (1983-2008), and Research Assistant at Max Planck Institute For Biophysical Chemistry (1978-1981). Dr. Südhof received his doctorate from RWTH Aachen University and his undergraduate degree from the University of Gottingen. |
| Patrick Kron |
Patrick Kron is the founder of Pkc&I SAS, serving as Chairman since 2016. Current jobs include Chairman of Imerys SA since 2020, Independent Chairman of Imerys SA since 2005, Independent Director of Sanofi since 2014, Non-Executive Director of Viohalco SA since 2020, and Director of Gentilly Verdun SNC. Former jobs include Chairman & Chief Executive Officer of Alstom SA from 2003 to 2016, Chief Executive Officer of Vivendi SE from 2005 to 2006, Chief Executive Officer of Imerys SA from 1998 to 2002, Chairman & Chief Executive Officer of FerroGlobe France SAS from 1988 to 2002, Chairman & Chief Executive Officer of Mersen France Amiens SAS from 1993 to 1997, Chairman of Mersen SA from 1993 to 1997, Chairman of Truffle Capital SAS from 2016 to 2024, Chairman of Carbone Lorraine Co. from 1993 to 1997, and various director roles at Bouygues SA, ElvalHalcor Hellenic Copper & Aluminium Industry SA, Association Française des Entreprises Privées, General Electric UK Holdings Ltd., Alstom Asia Pte Ltd., Holcim Ltd., Halcor Metal Works SA, Pechiney SA, Segula Technologies SA, and Vice President of Les Arts Florissants from 2013 to 2015. Education includes undergraduate degrees from Ecole Polytechnique and École Nationale Supérieure des Mines de Paris. |
| Fabienne Lecorvaisier |
Fabienne Lecorvaisier currently works at Sanofi, as Independent Director from 2013, Safran SA, as Independent Director, Aqua Lung, Inc., as Director, Air Liquide Eastern Europe SA, as Director, and Wendel SE, as Member-Supervisory from 2023. Ms. Lecorvaisier also formerly worked at Air Liquide Finance SA, as Chairman & Chief Executive Officer, Air Liquide USA LLC, as Chairman, Air Liquide International SA, as Director, Société d'Oxygene et d'Acetylene d'Extreme-Orient SA, as Director, Air Liquide Japan G.K., as Director, Essilor of America, Inc., as Director-Finance & Information Systems, Association Nationale des Sociétés par Actions, as Director, Air Liquide Welding SA, as Director, Aqualung International SA, as Director, Air Liquide Eastern Europe SA, as Director, Air Liquide France Industries SA, as Director, Essilor Group Canada Ltd., as Development Director from 1993 to 2001, Rexecode Services SA, as Director, The Hydrogen Co. SA, as Director, American Air Liquide Holdings, Inc., as Director, Société Générale SA, as Member-Corporate Finance Department from 1985 to 1989, Banque du Louvre, as Assistant General Manager from 1990 to 1993, Air Liquide SA, as Executive Vice President from 2021 to 2023, Taittinger SAS, as Assistant General Manager from 1990 to 1993, Air Liquide Italia SpA, as Vice President-Operations & Finance, Legion of Honor, as Officer, and Air Liquide International Corp., as Executive Vice President. Ms. Lecorvaisier received her undergraduate degree from Ecole Nationale des Ponts et Chaussées. |
| Rachel Duan |
Rachel Duan currently works at HSBC Holdings Plc, as Independent Non-Executive Director from 2021, Sanofi, as Independent Director from 2020, Adecco Group AG, as Independent Non-Executive Director from 2020, and Kering SA, as Independent Director from 2024. Ms. Duan also formerly worked at GE Aerospace, as Senior VP, President & CEO-Global Markets from 2019 to 2020, GE (China) Co., Ltd., as President & Chief Executive Officer, GE Healthcare (China) Co. Ltd., as Chief Executive Officer, GE Advanced Materials, as Chief Executive Officer, GE Plastics China Ltd., as Commercial Director, and AXA SA, as Independent Non-Executive Director from 2018 to 2025. Ms. Duan received her Masters Business Admin degree from the University of Wisconsin and undergraduate degree from Shanghai International Studies University. |
| Jean-Paul Kress |
Jean-Paul Kress currently works at Vor Biopharma, Inc., as Chairman, Chief Executive Officer & President from 2025, Syntimmune, Inc., as President & Director, and Sanofi, as Independent Director from 2025. Dr. Kress also formerly worked at Sanofi Pasteur MSD SNC, as President & Chief Executive Officer from 2011 to 2015, MorphoSys AG, as CEO & Chairman-Management Board from 2019 to 2024, ERYTech Pharma SA, as Chairman from 2019 to 2023, Sarepta Therapeutics, Inc., as Independent Director from 2015 to 2017, Quantum Genomics SA, as Director from 2018 to 2019, Biogen, Inc., as President-International & Executive Vice President from 2017 to 2018, Genzyme Corp., as Senior Vice President & Head-North America from 2015 to 2017, Gilead Sciences SAS, as Vice President-US Sales & Marketing, and Abbott France SAS, as General Manager-Denmark. Dr. Kress received his undergraduate degree in 1991 and graduate degree in 1992 from École Normale Supérieure and doctorate degree in 1991 from Faculté De Médecine Necker Enfants Malades Université. |
| Antoine Yver |
Antoine Yver currently works at Sanofi, as Independent Director from 2022, Spotlight Therapeutics, Inc., as Director from 2022, and Stipple Bio Inc., as Director. Dr. Yver also formerly worked at Centessa Pharmaceuticals Plc, as Executive Vice President & Chairman-Development from 2022 to 2024, Aventis SA, as Senior Director-Clinical Research from 1990 to 2005, Schering-Plough SAS, as Executive Director-Oncology from 2006 to 2009, Johnson & Johnson Medical SAS, as Senior Director-Oncology from 2005 to 2006, AstraZeneca PLC, as Head-Global Medicines Development from 2015 to 2016, and Daiichi Sankyo Co., Ltd., as EVP, Global Head-Oncology Research and Development from 2016 to 2021. Dr. Yver received his undergraduate degree and doctorate degree from Université Paris-Saclay. |
| Anne-Francoise Nesmes |
Anne-Francoise Nesmes currently works at Compass Group Plc, as Senior Independent Non-Executive Director from 2023, Merlin's Magic Wand Trustees Ltd., as Director, Merlin Entertainments Share Plan Nominee Ltd., as Director, Sea Life Trust Ltd., as Director from 2018, SEA LIFE Trustees Ltd., as Director, and Sanofi, as Independent Director from 2024. Ms. Nesmes also formerly worked at Smith & Nephew plc, as Chief Financial Officer & Executive Director from 2020 to 2024, Merlin Entertainments Ltd., as Chief Financial Officer & Executive Director from 2017 to 2020, GSK Plc, as Senior Vice President-Finance from 2009 to 2013, Dechra Pharmaceuticals Ltd., as Chief Financial Officer in 2016, and Genera dd, as Member-Management Board in 2015. Ms. Nesmes received her Masters Business Admin degree from Henley Business School Ltd. and graduate degree from Grenoble Ecole de Management. |
| Carole Gabriella Ferrand |
Carole Gabriella Ferrand currently works at Sanofi, as Independent Director from 2022, Terra Nova SAS, as Director from 2012, Société d'exploitation de l'hebdomadaire le Point SA, as Director, and France Télévisions SA, as Director. Ms. Ferrand also formerly worked at Isai Cap Venture, as Chairman, Société d'exploitation de l'hebdomadaire Le Point, as Director, Tallandier Éditions SA, as Director, Palazzo Grassi SpA, as Director, Off Nat Etudes Recherches Aerospatiales, as Director, Capgemini Service SAS, as Director, Capgemini Italia SpA, as Director, Fnac Darty SA, as Independent Director from 2013 to 2022, Artémis 21 SA, as Director, Pinault Collection SAS, as Director, Archer Obligations SA, as Director, Collection Pinault, as Director, June 21 SAS, as Director, Financière Pinault SCA, as Financing Director from 2013 to 2018, Capgemini UK Plc, as Director, Capgemini España SL, as Director, CGS Holdings Ltd., as Director, Altran Innovación SL, as Director, Capgemini Solutions Canada, Inc., as Director, Capgemini SE, as Chief Financial Officer from 2018 to 2024, EuropaCorp SA, as Chief Financial Officer from 2011 to 2012, Capgemini Technology Services India Ltd., as Chief Financial Officer, Sony Semiconductor Manufacturing Corp. (Japan), as Chief Financial Officer & General Counsel from 2000 to 2011, Sony France SA, as Chief Finance Officer & General Secretary from 2002 to 2011, PricewaterhouseCoopers France SARL, as Auditor from 1992 to 2000, and Capgemini Group, as Chief Financial Officer from 2018 to 2023. Ms. Ferrand received her undergraduate degree in 1992 from École des Hautes Études Commerciales de Paris. |
| Barbara Lavernos |
Barbara Lavernos currently works at L'Oréal SA, as Deputy CEO-Research, Innovation & Technology from 2021, Sanofi, as Non-Independent Director from 2021, and L'Oréal Canada, Inc., as Chief Technology, Operations Officer & EVP. Ms. Lavernos also formerly worked at Bpifrance SA, as Director, Bpifrance Participations SA, as Director, and Lactobio A, as Director. Ms. Lavernos received her undergraduate degree from École des Hautes Études d’Ingénieur. |
| Claudie Haigneré |
Claudie Haigneré is Member of Academie de l'air et de l'espace, Member of Académie des Sciences et Technologies, Member of Académie Des Sciences D'Outre-Mer and Member of Academie des Sports and on the board of 6 other companies.
In her past career she held the position of Chairman for Universcience.fr, Chairman at La Géode, Counselor at European Space Agency (France), Member of International Academy of Astronautics and Member of Académie des Technologies. |
| Clotilde Delbos |
Ms. Clotilde Delbos is an Independent Director at Sanofi, an Independent Director at AXA SA, a Chief Executive Officer at Mobilize Brand, an Independent Director at Alstom SA, an Independent Director at ALSTOM Holdings SA, a Co-Manager at Hactif Patrimoine, a Chairman at Hactif Advisory and a Co-Manager at Actif Patrimoine. She is on the Board of Directors at Sanofi, AXA SA, Alstom SA, ALSTOM Holdings SA and Schneider Electric SE. Ms. Delbos was previously employed as a Chairman by Renault SAS, a Member-Management Board by Renault-Nissan BV, a Member-Supervisory Board by Alliance Ventures BV, a Member-Management Board by Alliance Rostec Auto BV, a Chairman by RCI Banque SA, a Chief Financial Officer, Controller & Senior VP by Renault Group BV, a Deputy Chief Executive Officer & Executive VP by Renault SA, a Deputy CFO & Chief Risk Officer by CONSTELLIUM FRANCE SAS, a Financial Director-Bauxite Alumina Division by Pechiney Group, a Chairman by Alliance Ventures, a Chairman by Mobiliz Invest SAS, a Chairman by MOBILIZE VENTURES, and a Chairman by Renault Mobility as an Industry SAS. She also served on the board at Renault España SA. She received her undergraduate degree from Emlyon Business School. |
| John Sundy |
John Sundy currently works at Sanofi, as Independent Director from 2024 and Neutrolis, Inc., as Director. Dr. Sundy also formerly worked at Gilead Sciences, Inc., as Senior Vice President from 2014 to 2020, Duke University, as Associate Professor from 2006 to 2014, Duke-NUS Graduate Medical School Singapore, as Associate Professor from 2006 to 2014, and Pandion Therapeutics, Inc., as Chief Medical Officer. Dr. Sundy received his undergraduate degree from Bucknell University, doctorate degree from Drexel University College of Medicine, and doctorate degree from Hahnemann University. |
